Evidence map›Paper›PMID 31201346›Full record

ArticleScientific reports2019

High-throughput sequencing of IgG B-cell receptors reveals frequent usage of the rearranged IGHV4-28/IGHJ4 gene in primary immune thrombocytopenia.

Makoto Hirokawa, Naohito Fujishima, Masaru Togashi, Akiko Saga, Ayumi Omokawa, Tomoo Saga, Yuki Moritoki, Shigeharu Ueki, Naoto Takahashi, Kazutaka Kitaura and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. VDJ-REMIX: REpertoire Module Identification and eXploration.Bioinformatics (Oxford, England) · 2026
    Article
  2. Article
  3. Article
  4. How we treat primary immune thrombocytopenia in adults.Journal of hematology & oncology · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Makoto HirokawaDepartment of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan. mhirokawa@hos.akita-u.ac.jp.
Naohito FujishimaDivision of Blood Transfusion, Akita University Hospital, Akita, Japan.
Masaru TogashiDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Akiko SagaDepartment of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.
Ayumi OmokawaDepartment of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.
Tomoo SagaDepartment of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.
Yuki MoritokiDepartment of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.
Shigeharu UekiDepartment of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.ORCID http://orcid.org/0000-0002-3537-7735
Naoto TakahashiDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.ORCID http://orcid.org/0000-0002-6758-3787
Kazutaka KitauraRepertoire Genesis Incorporation, Ibaraki, Japan.
Ryuji SuzukiRepertoire Genesis Incorporation, Ibaraki, Japan.
Akita University · JPNational Sagamihara Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary immune thrombocytopenia (ITP) is an acquired form of thrombocytopenia caused by IgG anti-platelet autoantibodies and represents an organ-specific autoimmune disorder. Although the glycoprotein (GP)IIb/IIIa and GPIb/IX have been shown to be targets for autoantibodies, the antigen specificity of autoantibodies is not fully elucidated. To identify the characteristics of IgG B-cell receptor (BCR) repertoires in ITP, we took advantage of adaptor-ligation PCR and high-throughput DNA sequencing methods for analyzing the clone-based repertoires of IgG-expressing peripheral blood B cells. A total of 2,009,943 in-frame and 315,469 unique reads for IGH (immunoglobulin heavy) were obtained from twenty blood samples. Comparison of the IGHV repertoires between patients and controls revealed an increased usage of IGHV4-28 in ITP patients. One hundred eighty-six distinct IGHV4-28-carrying sequences were identified in ITP patients and the majority of these clones used an IGHJ4 segment. The IGHV4-28/IGHJ4-carrying B-cell clones were found in all ITP patients. Oligoclonal expansions of IGHV4-28/IGHJ4-carrying B cells were accompanied by multiple related clones with single amino substitution in the CDR3 region suggesting somatic hypermutation. Taken together, the expansion of IGHV4-28/IGHJ4-carrying IgG-expressing B cells in ITP may be the result of certain antigenic pressure and may provide a clue for the immune pathophysiology of ITP.

Indexed as

Gene RearrangementHigh-Throughput Nucleotide SequencingAdultAmino Acid SequenceClone CellsComplementarity Determining RegionsHumansImmunoglobulin GMiddle AgedPurpura, Thrombocytopenic, IdiopathicReceptors, Antigen, B-CellSomatic Hypermutation, ImmunoglobulinVaccinationComplementarity Determining RegionsImmunoglobulin GReceptors, Antigen, B-Cell

Identifiers

PMID31201346
PMCPMC6570656
OpenAlexW2951845541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.